NanoBio Starts Study Of Second Tolerability For Intranasal Vaccine
ANN ARBOR - Building upon a series of successful preclinical and clinical studies, NanoBio Corporation today announced the initiation of a second tolerability and immunogenicity study designed to test and further optimize its novel nanoemulsion-based intranasal vaccine adjuvant. In 2009, NanoBio tested its nanoemulsion adjuvant in combination with the commercial influenza vaccine Fluzone, in a